Parkinson's Disease Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)

DelveInsight's, "Parkinson's Disease Pipeline Insight 2023" report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in Parkinson's Disease pipeline landscape. It covers the Parkinson's Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson's Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Parkinson's Disease Pipeline Report
• DelveInsight's Parkinson's Disease pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Parkinson's Disease treatment.
• The leading companies working in the Parkinson's Disease Market include Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
• Promising Parkinson's Disease Pipeline Therapies in the various stages of development include BIIB122, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, KM-819, and others.
• March 2023: Neurocrine Biosciences announced a study of phase 2 clinical trials for VY-AADC02. The objectives of this study are to assess the efficacy, safety and tolerability of VY-AADC02 in Patients with Parkinson's Disease with Motor Fluctuations.
• July 2023: Hoffmann-La Roche announced a study of phase 2 clinical trials for Prasinezumab. This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

Request a sample and discover the recent advances in Parkinson's Disease Treatment Drugs @ Parkinson's Disease Pipeline Report- https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Parkinson's Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson's disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Parkinson's Disease Overview
Parkinson's disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine.

Find out more about Parkinson's Disease Treatment Drugs @ Drugs for Parkinson's Disease Treatment- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Parkinson's Disease Emerging Drugs Profile
• Tavapadon: Cerevel Therapeutics
• IkT-148009: Inhibikase Therapeutics
• NLY01: Neuraly
• PT320: Peptron

Parkinson's Disease Pipeline Therapeutics Assessment
There are approx. 140+ key companies which are developing the Parkinson's Disease therapies. The Parkinson's Disease companies which have their Parkinson's disease drug candidates in the most advanced stage, i.e. phase III include, Cerevel Therapeutics.

Learn more about the emerging Parkinson's Disease Pipeline Therapies @ Parkinson's Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Parkinson's Disease Pipeline Report
• Coverage- Global
• Parkinson's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Parkinson's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Parkinson's Disease Companies- Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
• Parkinson's Disease Pipeline Therapies- BIIB122, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, KM-819, and others.

Dive deep into rich insights for new drugs for Parkinson's Disease treatment, Visit @ Parkinson's Disease Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Parkinson's Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Parkinson's Disease - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tavapadon: Cerevel Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Prasinezumab : Roche
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MEDI1341: AstraZeneca
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Neural microtissues: Treefrog Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Parkinson's Disease Key Companies
21. Parkinson's Disease Key Products
22. Parkinson's Disease- Unmet Needs
23. Parkinson's Disease- Market Drivers and Barriers
24. Parkinson's Disease- Future Perspectives and Conclusion
25. Parkinson's Disease Analyst Views
26. Parkinson's Disease Key Companies
27. Appendix

For further information on the Parkinson's Disease pipeline therapeutics, reach out to Parkinson's Disease Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Important Published Links-

https://aeros.mn.co/posts/45751762
https://churecipe.mn.co/posts/45751826
https://itravel.mn.co/members/20248979
https://hubvin.mn.co/posts/45752020
https://drujrake.mn.co/posts/45752126
https://together.mn.co/posts/45752522
https://bipolarjungle.mn.co/posts/45752571
https://mossfon.mn.co/posts/45752666
https://create-lifestyle.mn.co/posts/45753329
https://gelardas.mn.co/members/20249381
https://bloby.mn.co/posts/45753578
https://cic-mun.mn.co/posts/45753710
https://www.exchangle.com/dennydones9
https://old.meneame.net/user/dennydones9
https://gsap.com/community/profile/159086-denny-dones/
https://www.pling.com/u/dennydones9/
https://shaunbook.mn.co/posts/type-1-diabetes-market-size-forecast-and-outlook-2032
https://zip-launchpad.mn.co/posts/45579349
https://dj-club-sf.mn.co/posts/45579415
https://wwwpreparatorianis.mn.co/posts/45579543
https://www.projectnoah.org/users/dennydones9
https://naijases.mn.co/posts/type-1-diabetes-market-future-trends-and-opportunities
https://indicate.mn.co/posts/45580238
https://linkasia.mn.co/posts/45580415
https://playhq.mn.co/posts/45580609
https://coco-quinn.mn.co/posts/45580757
https://www.storeboard.com/JohnSmith-5965202
https://doodleordie.com/profile/dennydones99
https://macro.market/company/delveinsight-business-research
https://pantip.com/profile/7306022#topics
https://allmylinks.com/dennydonesusa
https://uconnect.ae/read-blog/4382
https://blacksnetwork.net/post/102497_herpetic-keratitis-is-a-condition-that-affects-the-eye-and-is-caused-by-the-herp.html
https://ekonty.com/-dennydones99
https://app.wedonthavetime.org/posts/03e285b9-e449-4c96-b257-8cb7a2b74243
https://www.weddingbee.com/members/dennydones99/
https://community.storytellingwithdata.com/members/me/gallery
https://participer.valdemarne.fr/profiles/denny_dones/activity
https://elderassociation.mn.co/posts/45117025
https://www.domestika.org/en/dennydones99
https://nxgen.mn.co/members/19995548
https://www.laclt.com/profile/ybhardwaj/profile
https://stemfemmes.mn.co/posts/emerging-trends-in-managing-hot-flashes-in-the-prostate-cancer-market
https://network-91053.mn.co/posts/45119865
https://autism-support.mn.co/posts/understanding-hot-flashes-in-prostate-cancer-market-size-and-outlook-2032
https://jasa-seo.mn.co/posts/45120226
https://lapp.unl.edu.ec/profiles/dennydones99/activity?locale=en
https://imarticus.org/skillenza/user/dennydones9
https://oppathingzz.mn.co/members/20019648
https://findaspring.org/members/dennydones9/
https://www.poeticous.com/yashveer-bhardwaj
https://git.disroot.org/dennydones9
https://kuula.co/profile/havensmith
https://artmight.com/user/profile/3082810
https://www.credly.com/users/denny-dones/badges
https://quantum-buoyancy.mn.co/posts/axillary-hyperhidrosis-market-size-and-outlook-delveinsight
https://freeline.mn.co/posts/45202136
https://3dwarehouse.sketchup.com/user/0e9f9584-794e-4467-ac59-79db9efbadd9/Denny-Dones
https://www.hackster.io/dennydones9
https://letterboxd.com/dennydones9/
https://ko-fi.com/dennydones9
https://wakelet.com/@DennyDones813
https://onedio.com/profil/dennydones9
https://www.lyrics.com/user/349564/dennydones9#google_vignette
https://hypothes.is/users/dennydones9
https://shivambhu-hut.mn.co/posts/exploring-the-axillary-hyperhidrosis-market-innovations-treatments-and-future-prospects
https://zumvu.com/dennydones9/
https://onlyfans.com/dennydones9
https://maker.wiznet.io/dennydones9
https://collab.sundance.org/people/Denny-Dones-1699939772
https://insurtechasia.mn.co/posts/45403575
https://meganto-lottery.mn.co/posts/45403650
https://ylimun.mn.co/posts/45403740
https://network-79379.mn.co/posts/45404061
https://acatpg.mn.co/posts/45404422
https://brooklynneo.mn.co/posts/45404495
https://ucat-bootcamp.mn.co/posts/45404540
https://coding-playground.mn.co/posts/45404600
https://living-word-network.mn.co/posts/45404653
https://treadmill.mn.co/posts/45459156
https://chineseintheus.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast
https://wear.net/dennydones9/
https://productinn.mn.co/posts/parkinsons-disease-market-outlook-and-forecast-report-2032
https://justchatting.mn.co/posts/45460636
https://expressyourcurve.mn.co/posts/45460860
https://clinalleve.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast-2032
https://nhattao.com/members/user6331540.6331540/
https://seedly.sg/profile/denny-dones/
https://note.com/denny_dones/n/n489e5dd1ff1a
https://www.uplabs.com/dennydones9
https://www.zazzle.com/mbr/238605385879691977
https://independent.academia.edu/HavenSmith2
https://play.eslgaming.com/player/19736877/
https://creators.audiomack.com/dennydones1
https://piano.masto.host/@dennydones9
https://tech4goodwales.mn.co/posts/the-evolving-landscape-of-the-major-depressive-disorder-market
https://worldletinews.mn.co/members/20156129
https://community.greeka.com/users/dennydones9

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.